Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 vs olmesartan on arterial stiffness in elderly hypertension
jRCT2080222043Phase 2
- Sponsor
- Novartis
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sacubitril + valsartan in essential hypertension (2 arms), sponsored by Novartis. Primary endpoint: Change in central blood pressure / arterial stiffness over 52 weeks.
02
Drugs
sacubitril + valsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCT2080222043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222043.